Choosing Decentralized Clinical Trials
The Rise of DCTs
The COVID-19 pandemic has challenged the viability of traditional clinical trials around the world. The use of decentralized clinical trial (DCT) options was on the rise before the pandemic, but the industry’s growing need to keep research moving forward and ensure the safety of clinicians and patients made the need for remote capabilities more important than ever. With new efficiencies produced by telemedicine, remote monitoring, direct-to-patient shipments, devices and more, these new options will remain an important attribute of clinical trials as we enter the digital age of research.
Why Choose DCTs
As the clinical landscape continues to evolve, DCTs present opportunities to emphasize convenience, safety and flexibility, while continuing to pursue quality data and valuable research. Advantages include:
PPD is dedicated to creating environmental innovations to better predict, measure and identify strategies to reduce the greenhouse gas emissions on clinical trials. We are partnering with stakeholders across the clinical trial spectrum to better understand how we can digitize, decentralize and modernize clinical research to make it more environmentally friendly.
2021-2022 DECENTRALIZED CLINICAL TRIALS INDUSTRY REPORT
In 2021, after pandemic-fueled growth in decentralized clinical trials, PPD mined industry opinions on the likely future composition of clinical trial operations. The analysis aimed to determine how hybrid and fully decentralized models will be used alongside traditional constructs in efforts to increase efficiency, improve outcomes, and speed the progress of life-saving therapeutics.
Access the data and insights on how the industry is pivoting to tackle clinical trials during the pandemic and beyond.
What Are Some of the Challenges Sites Experience When Implementing DCTs?
Decentralized clinical trials (DCTs) span a broad spectrum of designs and iterations, the bulk of which are currently hybrid trials that include some aspects of both digitally enabled and decentralized approaches. While sites may experience some challenges, sponsors and clinical research organizations (CROs) can take steps to support site staff. Working with a DCT vendor — one who is reliable and consistent, has a proven track record and delivers high quality — is crucial for success.
Learn about how PPD’s white-glove service supports sites on their DCT journey. Access the article below.
Evolving Solutions to Optimize Clinical Trial Decentralization
As the adoption of decentralized and hybrid clinical trials continues to grow, trial designers and researchers are increasingly adopting novel solutions and new technologies to decrease patient burden and increase levels of successful adherence.
See how PPD is removing the rigidity associated with traditional trial design and focusing on innovation and patient centricity. Access the article below.
PPD NAMED A LEADER IN DIGITAL TRANSFORMATION BY ISG
Information Services Group (ISG) recognized PPD in its 2022 ISG Provider Lens™ Life Sciences Digital Services Global Report that assesses the use of technology innovation to assist in drug development. The honorees were determined following a nine-month research study, in which providers were independently evaluated. The findings recognize PPD as an ISG Provider Lens Leader for clinical development digital transformation services and patient engagement digital transformation.
2020 CLINICAL TRIAL INSIGHTS REPORT
To guide organizations through a transformative time in clinical research, PPD held a number of webinars exploring the accelerated pace of adoption for novel approaches and innovations impacting clinical research, with our experts offering strategies and considerations to support the rapid changes happening within clinical trial design and operations.
Examining Implementation Timelines For Decentralized Clinical Trials (Dcts)
While DCTs can still enable trials that would otherwise be challenging during the pandemic, many of the potential efficiencies — particularly rapid implementation — can remain out of reach. PPD has DCT strategies built into the protocol from the start, with custom features and functions instead of a one-size-fits-all approach.
Learn more about implementation timelines for decentralized trials.
Building Decentralized Clinical Trials for Patients and Clinicians
The increased implementation of decentralized clinical trials means the industry now has a considerable body of evidence and experience to test the strengths of digital clinical trial models. With the growing amount of data comes the ability to assess how to make trials more effective and efficient, including a closer look at qualitative sponsor, site and patient feedback. To gain further insight into this transformation, PPD explored the experiences that key stakeholders have had when approaching decentralized clinical trials.
Digital Innovation & Implementation
How can PPD’s suite of digital capabilities and solutions help you reach more patients?